Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Follow-Up Questions
Who is the CEO of Monopar Therapeutics Inc?
Dr. Chandler Robinson is the Chief Executive Officer of Monopar Therapeutics Inc, joining the firm since 2014.
What is the price performance of MNPR stock?
The current price of MNPR is $63.86, it has decreased 3.6% in the last trading day.
What are the primary business themes or industries for Monopar Therapeutics Inc?
Monopar Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Monopar Therapeutics Inc market cap?
Monopar Therapeutics Inc's current market cap is $394.0M
Is Monopar Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Monopar Therapeutics Inc, including 2 strong buy, 9 buy, 2 hold, 0 sell, and 2 strong sell
